As in the general population, improvements in all-cause and cardiovascular mortality were seen, but these were smaller in patients with type 2 diabetes.
Investigators made use of the Swedish National Diabetes Register to investigate trends in all-cause mortality and cardiovascular disease in 36,869 people with type 1 diabetes and 457,473 with type 2 diabetes.
The baseline mean glycated hemoglobin level was 8.2% in people with type 1 diabetes and 7.1% in those with type 2 diabetes. Mean duration of diabetes before entry into the registry was 20 years in the diabetes type 1 group and 6 years in the type 2 group. During follow-up (median, 15 years), both diabetes groups had decreases in mean LDL cholesterol and blood pressure.
The researchers examined mortality in the diabetes groups and in separate general-population groups matched by age, sex, and county. All-cause mortality declined by 31 dea…
Reviewing Author
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association
DisclosuresConsultant/Advisory BoardUnited Healthcare; Element Science; Eyedentifeye, F-Prime
EquityHugo Health; Refactor Health; Element Science
Grant/Research SupportPfizer; Agency for Healthcare Research and Quality; Janssen Research and Development, National Institute of Biomedical Imaging and Engineering; National Heart, Lung, and Blood Institute; Centers for Disease Control and Prevention; National Cancer Institute; American Heart Association